$0.5300
-0.0101-1.87%
Kairos Pharma Ltd (KAPA) Stock Price, Quote, News & History
KAPAAMEX
Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metastatic prostate cancer patients.
You can purchase shares of Kairos Pharma (AMEX:KAPA) through any online brokerage.
Other companies in Kairos Pharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Kairos Pharma has a consensus price target of $59.50.
The stock price for Kairos Pharma (AMEX: KAPA) is $ last updated .
There are no upcoming dividends for Kairos Pharma.
Kairos Pharma does not have any upcoming earnings scheduled.
There is no upcoming split for Kairos Pharma.
Kairos Pharma is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and...
